Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I agree finishing the BLA will help everything. C

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154746
(Total Views: 392)
Posted On: 09/19/2019 7:03:28 AM
Avatar
Posted By: trding
Re: plavac #8313
I agree finishing the BLA will help everything. CYDY has been in BLA limbo for 6 months after part 1 was submitted in March, TNBC limbo for 8 months really with the NC conference in January , mono limbo for 4 mono after the pivotal trial submitted in May, and partnership/financing limbo for a year while they continue to use Paulson. I understand the frustration of some, but all of that ends soon. Getting Part 2 of the BLA done will greatly help. Mono meeting shortly, lasted September or early October. TNBC screening at least some progress. Partnership, cydy has accepted one at least, waiting on the other company dd or milestone sounds like, and others interested. With NP saying they are working on financing to the end of the year, that is when the BLA will be done, worst timeline, and probably milestone payments kick in no matter if the partnership is signed tomorrow or next month. So, they are close, and finishing the BLA is key. Getting financing until that point is the second key, we will see how much they raise. Having the partnership/financing in place before or at the same time as submission to fund operations after BLA submission is the third key. Again a majority of the burn rate is spent on the current mono trial, they indicated in 10k they wanted to stop in that trial after mono pivotal is approved and data needed, for BLA is done , we will see what the fda says. The second burn rate is going to BLA, NP said, what, 50 people working on it, plus the cmo cost over the last three years to prepare for it. The other items are just small potatoes that gives us something to talk about while we wait on the big items to get done.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us